Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Acurx Pharmaceuticals ( (ACXP) ) is now available.
Acurx Pharmaceuticals announced a 1-for-20 reverse stock split of its common stock, effective August 4, 2025, to comply with Nasdaq’s minimum bid price requirement. This move will reduce the number of outstanding shares significantly and is expected to impact trading on August 5, 2025, under a new CUSIP number while maintaining the current ticker symbol ‘ACXP’.
The most recent analyst rating on (ACXP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Acurx Pharmaceuticals stock, see the ACXP Stock Forecast page.
Spark’s Take on ACXP Stock
According to Spark, TipRanks’ AI Analyst, ACXP is a Underperform.
Acurx Pharmaceuticals’ score reflects the challenges of an early-stage biotech, including lack of revenue and ongoing losses, balanced by strong potential in clinical advancements and regulatory support. Technical indicators suggest weak momentum, and valuation is hindered by financial fundamentals.
To see Spark’s full report on ACXP stock, click here.
More about Acurx Pharmaceuticals
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company’s research and development pipeline includes antibiotic candidates targeting Gram-positive bacteria, such as Clostridioides difficile and methicillin-resistant Staphylococcus aureus (MRSA). Acurx’s lead product candidate, ibezapolstat, is Phase 3 ready, with plans to begin international clinical trials next year.
Average Trading Volume: 6,361,737
Technical Sentiment Signal: Sell
Current Market Cap: $11.6M
For an in-depth examination of ACXP stock, go to TipRanks’ Overview page.